Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
treatment-resistant depression
Biotech
Lilly inks $2.8B AtaiBeckley psychedelic buyout to challenge J&J
Continuing its takeover spree, Lilly is moving into a psychedelic mental health sector targeted by companies including Johnson & Johnson.
Nick Paul Taylor
Jul 16, 2026 7:32am
Compass guides psychedelic to 2nd pivotal depression win
Feb 17, 2026 8:39am
Cyclerion emerges from latest pivot as neuro biotech
Sep 24, 2025 4:15am
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Jul 1, 2025 8:30am
Compass' psychedelic therapy wins ph. 3, investors unimpressed
Jun 23, 2025 8:05am
Supernus depression drug candidate fails midstage trial
Feb 19, 2025 6:40am
